To study and compare the Efficacy of L.M. Scale vis-a-vis Centesimal scale of Potency in Management of type-2 Diabetes Mellitus

DR PARTH APHALE0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Inclusion Criteria4:
•1.Male& female subjects between the ages of 18 and 70 years, inclusive, with Type 2 diabetes mellitus as defined by the American Diabetes Association (Diabetes care, Vol. 21: S5- S19, 1998) for more than one year.
•2.Blood sugar levels- a. Fasting- 120-150 mg/dl b. Post-prandial- 140-200 mg/dl
•3.Random blood sugar level-140-200 mg/dl
•HbA1C 6-10mg%)
•4.Subjects must be off all oral hypoglycemic agents during the entire duration of study with prior written consent.
•5.Subjects must refrain from strenuous physical activity beginning 72 hours prior to admission and through the duration of the study.
•6.Subjects must be willing and able to provide written informed consent

•TYPE-1 DIABETES MELLITUS
•Subjects with â??brittleâ?? diabetes or predisposition to severe hypoglycemia, e.g., 2 or more serious hypoglycemic episodes (requiring anotherâ??s assistance) within the past year, or any hospitalization or emergency room visit due to poor diabetic control within the past 6 months
•Evidence of significant active hematological disease and/or cumulative blood donation of 1 unit (500 mL) or more including blood drawn during clinical trials in the last 3 months.
•Evidence of significant active neuropsychiatric disease.
•CHRONIC ALCOHOLIC
•Intake of any drug which in the evaluation of the investigator may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilisation or recovery from hypoglycemia.
•ON INSULIN THERAPY
•Have any other condition (including drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol.
•History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological or infectious disorders capable emerging as a potent risk factor when taking the study medication.

发起方

DR PARTH APHALE